An observational study in Neurological Disorders, sponsored by Assiut University. Status unknown. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-10-31.
Sponsored by Assiut University · Observational
The aim of the study is to determine neurological and cognitive disorders in children with congenital heart disease for early diagnosis and treatment
Congenital heart defects are significant structural abnormalities affecting the heart and major intrathoracic vessels. They are among the most common birth defects, constituting about one-third of all major congenital anomalies. Many of these defects necessitate surgical intervention during early childhood. Advances in surgical techniques have significantly improved survival rates for patients with congenital heart disease (CHD). However, a variety of systemic complications have become more apparent, including issues affecting the cardiac, pulmonary, gastrointestinal, neurological, and nephrological systems (Walaa El Naga et al., 2022).
Neurological complications greatly contribute to morbidity and mortality in pediatric CHD patients, significantly impacting their neurodevelopmental outcomes. Various studies indicate that up to 30% of children with congenital heart disease (CHD) experience neurological complications. Seizures are the most frequently reported neurological complication, accounting for approximately 70% of cases with neurological sequelae (Aly El Kazaz et al., 2022).
Also Neuropsychological studies of children with complex CHD reveal distinct deficits in intelligence, cognitive performance, executive function, language skills, visuospatial abilities, and attention. (Guo et al., 2021). Recognizing the long-term consequences of accumulated brain injury underscores the importance of identifying and minimizing early insults. (Le H.Sterling et al., 2021) The recognized neurodevelopmental challenges faced by children with CHD prompted the American Heart Association to recommend routine neurodevelopmental evaluations for high-risk patients with CHD. According to the American Heart Association, the initial visit, conducted before 12 months of age, should include a neuromotor examination assessing muscle tone, primitive and deep tendon reflexes, sensory status, and gross motor skills. Although many children with CHD now undergo these recommended neurological examinations, the examinations and their outcomes have not been thoroughly described. Additionally, factors predicting abnormal neurological examination results have not been identified. Enhancing our understanding of the findings from these routinely recommended evaluations will improve the detection of abnormalities, thereby optimizing support for children with CHD and their families.(Le Samantha butler et al., 2023).
985 studies on the registry are indexed under Nervous System Diseases; 251 are open to participants now.
This study's planned enrollment of 100 is below the median of 122 across 322 observational studies indexed under Nervous System Diseases.
Browse Nervous System Diseases studies →Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Children from 3 years to 18 years with congenital heart disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Children from 3 years to 18 years with congenital heart disease
Exclusion Criteria:
Radiation: CT · Radiation: CT scan
CT Brain
Neuroimaging in case with delayed development , focal neurological symptoms or seziures
The aim of the study is to determine neurological and cognitive disorders in children with congenital heart disease for early diagnosis and treatment.
Time frame: one year
No study locations are listed for this record.
Plan to share: No
Start is estimated for Oct 2024; primary completion for Oct 2025, 12 months later.
Of 133 non-industry observational studies under Nervous System Diseases, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 121. This study's planned 12 months is below that.
Counting every sponsor, half of 148 studies reached it within 50 months; a quarter within 15 and three quarters within 121.
Nervous System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.